The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
Approach: Treg immune modulation.
Indications: Oncology and autoimmune diseases.
The company has already announced a corporate strategic research alliance with Takeda with the goal of validating novel tumor-infiltrating regulatory Treg targets against which Takeda will develop potential therapies.
Egle’s flagship program focuses on the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
Established in 2020, the start-up results from Eliane Piaggio’s research work, as Inserm Research Director & Head of the Translational Immunotherapy Team at Institut Curie, and Luc Boblet, a serial biotech entrepreneur.
Subscribe for alerts on new companies featured on Startups.Bio
- MoonLake ImmunotherapeuticsMoonLake Immunotherapeutics is a Swiss biopharmaceutical company leveraging single-domain antibody (Nanobody®) technology […]
- ResBioticResBiotic is developing microbiome-based products to help reduce inflammation in chronic lung […]
- Alchemab TherapeuticsAlchemab identifies naturally occurring protective antibodies that counter complex diseases, such as […]
- Wild BiotechIsrael-based Wild Biotech is mining wild animal microbiomes for the discovery of […]